samedan logo
 
 
 
spacer
home > ebr > spring 2008 > collaborate to innovate
PUBLICATIONS
European Biopharmaceutical Review

Collaborate to Innovate

Heather Fraser at the IBM Institute for Business Value discusses the importance of establishing a strong basis for biopharmaceutical collaborations, and explores the ways to ensure that they work for the life of the alliance

Biopartnering the sourcing, formation and management of alliances is now a multi-billion dollar business. Between 2004 and 2006 the number of alliances remained fairly constant, but their value tripled from US$30 billion to US$90 billion according to data from Recombinant Capital (1). Some US$30 billion worth of new deals were announced in 2006 alone. US biotech companies still dominate the industry, and European firms remain the preferred partners of those operating outside North American borders, according to recent research by Datamonitor (2). But the Asian biotech sector is also expanding rapidly, as changing regulations and better access to large patient populations make the region a more attractive place in which to conduct Phase I trials (3).

Given the rising value and increasing geographic spread of the biopartnering market, the ability to create successful alliances is becoming vital. In 2006, we conducted our fourth survey of biotech and pharmaceutical companies, along with Silico Research, to identify the key alliance-making trends (4). Our survey draws on the responses of 312 individuals from 235 companies. Seventy-four per cent work for biotech companies and 26 per cent for pharmaceutical companies. Fifty-two per cent are based in the US, reflecting the composition of the sector by market share.

EMERGING TRENDS IN BIOPARTNERING

The results of the 2006 survey confirm a troubling trend that first emerged in 2000. Despite the maturing of the biopartnering market, biotech companies reported that 52 per cent of the alliances in which they had participated during the previous five years failed to live up to their expectations. This is marginally better than the situation at the start of the decade, when the failure rate was 59 per cent but it is hardly encouraging.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Heather Fraser is a Pharmacist with over 20 years of industry experience and has held positions within R&D, consultancy and community pharmacy. Heather is currently the global leader of the Life Sciences & Pharmaceuticals team at the IBM Institute for Business Value.
spacer
Heather Fraser
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

First cellularized collagen membrane implant to regenerate heart tissue in patients with ischemic heart disease

• 3P Biopharmaceuticals and Viscofan go ahead with this innovative project of regenerative medicine for cardiac use • Beginning of Phase I clinical trial in a group of 10 patients
More info >>

White Papers

Accelerating the Time from DNA to Material

Merck

Cell line development is a critical step in upstream process development for monoclonal antibodies (mAbs). Unfortunately, the search for the bestproducing clone can be labor- and resource-intensive and is often compared with looking for a needle in a haystack. Cells must first be engineered to produce the biologic of interest and the cell line generated from a high producing clone must deliver a sufficiently high titer to support clinical studies, and ultimately commercialization of the therapeutic.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement